SLC5A2 and heart failure: Therefore, in 2022, the American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA) guidelines for heart failure management have included SGLT-2 inhibitors as a standard treatment for patients with HFrEF [17].